PMID- 21639813
OWN - NLM
STAT- MEDLINE
DCOM- 20110928
LR  - 20181201
IS  - 1744-7666 (Electronic)
IS  - 1465-6566 (Linking)
VI  - 12
IP  - 10
DP  - 2011 Jul
TI  - Review of approved pioglitazone combinations for type 2 diabetes.
PG  - 1571-84
LID - 10.1517/14656566.2011.567266 [doi]
AB  - INTRODUCTION: Pioglitazone is approved in combination with several other 
      blood-glucose-lowering drugs for the treatment of type 2 diabetes mellitus 
      (T2DM). Beyond lowering blood glucose levels, each combination of different 
      blood-glucose-lowering drugs for the treatment of T2DM evolves specific 
      pleiotropic effects, which might be considered on an individual basis in a 
      certain patient. AREAS COVERED: The objective of this article is to provide a 
      short review of the pathophysiology of T2DM and to provide a rationale for the 
      combination of pioglitazone with other antidiabetic drugs, based on a 
      pathophysiological understanding of T2DM. Therefore, a PubMed search was 
      undertaken covering the search terms 'pioglitazone', 'antidiabetic drugs' and 
      'combination therapy'. EXPERT OPINION: Treatment with pioglitazone in T2DM was 
      shown to improve insulin resistance and blood glucose levels without increasing 
      the risk of hypoglycemia. Beyond those metabolic activities, pioglitazone was 
      shown to evolve anti-inflammatory and anti-atherogenic effects. It seems useful 
      to combine different antidiabetic drugs based on the specific needs and 
      contraindications in an individual patient. The treating of T2DM patients by 
      addressing not only glucose control, but also the underlying pathophysiological 
      etiology might help to improve patient prognosis in the long run, especially with 
      regard to the vascular complications.
CI  - (c) 2011 Informa UK, Ltd.
FAU - Forst, Thomas
AU  - Forst T
AD  - IKFE - Institute for Clinical Research and Development, Parcusstr. 8, D-5116 
      Mainz, Germany. thomasf@ikfe.de
FAU - Hanefeld, Markolf
AU  - Hanefeld M
FAU - Pfutzner, Andreas
AU  - Pfutzner A
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20110604
PL  - England
TA  - Expert Opin Pharmacother
JT  - Expert opinion on pharmacotherapy
JID - 100897346
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Blood Glucose)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Thiazolidinediones)
RN  - X4OV71U42S (Pioglitazone)
SB  - IM
CIN - Expert Opin Pharmacother. 2011 Jul;12(10):1457-61. PMID: 21651446
MH  - Anti-Inflammatory Agents/administration & dosage/adverse effects/pharmacology
MH  - Blood Glucose/drug effects
MH  - Diabetes Mellitus, Type 2/complications/*drug therapy/physiopathology
MH  - Drug Therapy, Combination
MH  - Humans
MH  - Hypoglycemia/chemically induced
MH  - Hypoglycemic Agents/administration & dosage/adverse effects/*pharmacology
MH  - Insulin Resistance
MH  - Pioglitazone
MH  - Prognosis
MH  - Thiazolidinediones/administration & dosage/adverse effects/*pharmacology
EDAT- 2011/06/07 06:00
MHDA- 2011/09/29 06:00
CRDT- 2011/06/07 06:00
PHST- 2011/06/07 06:00 [entrez]
PHST- 2011/06/07 06:00 [pubmed]
PHST- 2011/09/29 06:00 [medline]
AID - 10.1517/14656566.2011.567266 [doi]
PST - ppublish
SO  - Expert Opin Pharmacother. 2011 Jul;12(10):1571-84. doi: 
      10.1517/14656566.2011.567266. Epub 2011 Jun 4.